Status: Recruiting
A Study of Amorphous Calcium Carbonate in Postmenopausal Women
Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.
Participants needed: 205
Trial details
Age: 60-90Biological sex: FemaleType: InterventionalSponsor: Universal Integrated Corp.Updated: Mar 7, 2025Locations: 1
Eligibility criteria
Postmenopausal women who are 60 to 90 years of age. [+5]
Subjects who had conditions that influence bone metabolism (i.e., Paget's diseas... [+8]